Hemodialysis unit, Department of Nephrology, Chang Gung Memorial Hospital, Taipei, Taiwan.
Department of Health Care Management and Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan.
Sci Rep. 2019 Jul 24;9(1):10708. doi: 10.1038/s41598-019-47065-z.
Vascular access (VA) is the cornerstone for carrying out hemodialysis, yet it may bring in complications and leads to hemodialysis quality decline. This study aimed to explore the impact of vascular access types, including arteriovenous shunts and central venous catheter on all-cause mortality after adjustment of other risk factors. Total 738 ESRD patients aged over 40 year old receiving regular hemodialysis therapies were recruited between January 2001 and December 2010 from a single hemodialysis center in northern Taiwan. We ascertained the causes and date of death by linking our hospital database with Nationwide Mortality Registry Database. VA types and biochemistry parameters were extracted from the electronic hospital records. Patients were categorized into three groups, including (1)arteriovenous shunts (AVF)/arteriovenous shunts with Gortex®(AVG); (2)AVF/AVG combined central venous catheter; (3)catheter only. The time-dependent influence of vascular types i.e. initiation and follow-up period was also assessed. The mean follow-up time was 4.5 years. In patients using central venous catheter for initiation of hemodialysis, the adjusted hazard ratio (HR) for all-cause mortality was 1.55(95%CI: 1.09, 2.21), when compared with AVF/AVG. In the follow-up period, after adjustment for other risk factors, the multivariable analysis showed that the adjusted HRs were 3.23(95%CI: 1.85, 5.64) and 1.45(95%CI: 1.11, 1.91) for catheter only and AVF/AVG plus catheter, respectively. Our results showed that vascular accesses used for hemodialysis had different and time-dependent impact on patients' long-term survival. Patients who started hemodialysis with central venous catheter had significantly higher all-cause mortality rate. Furthermore, in the follow-up period, patients both in the catheter only and AVF/AVG plus catheter groups also had the significant all-cause mortality rates. Our results support the early establishment of arteriovenous shunt for the chronic kidney disease patients.
血管通路(VA)是进行血液透析的基石,但它可能带来并发症,并导致血液透析质量下降。本研究旨在探讨血管通路类型(包括动静脉瘘和中心静脉导管)在调整其他危险因素后对全因死亡率的影响。总共招募了 738 名年龄在 40 岁以上的接受常规血液透析治疗的终末期肾病患者,他们于 2001 年 1 月至 2010 年 12 月期间在台湾北部的一家单一血液透析中心接受治疗。我们通过将医院数据库与全国死亡率登记数据库进行链接,确定了死因和死亡日期。VA 类型和生化参数从电子病历中提取。患者被分为三组:(1)动静脉瘘(AVF)/动静脉瘘加戈尔(AVG);(2)AVF/AVG 联合中心静脉导管;(3)仅导管。还评估了血管类型的时间依赖性影响,即起始和随访期。平均随访时间为 4.5 年。在使用中心静脉导管开始血液透析的患者中,与 AVF/AVG 相比,全因死亡率的调整后危险比(HR)为 1.55(95%CI:1.09,2.21)。在随访期间,在调整其他危险因素后,多变量分析显示,仅导管和 AVF/AVG 加导管的调整后 HR 分别为 3.23(95%CI:1.85,5.64)和 1.45(95%CI:1.11,1.91)。我们的结果表明,用于血液透析的血管通路对患者的长期生存有不同的、时间依赖性的影响。使用中心静脉导管开始血液透析的患者全因死亡率显著更高。此外,在随访期间,仅导管组和 AVF/AVG 加导管组的患者全因死亡率也显著升高。我们的研究结果支持对慢性肾脏病患者早期建立动静脉瘘。